Erosion risks

• Price controls / tenders (e.g., China VBP) compress premium pricing
• Feature/clinical evidence parity from competitors
• Brand damage from quality or safety issues

Leading indicators

• Implantology market share trend
• Premium mix (share of premium SKUs within implant sales)
• New product adoption (e.g., flagship implant system volumes)

Counterarguments

• Competitors have comparable clinical evidence and premium brands, limiting differentiation
• Patients and clinics may trade down in price-sensitive markets

Erosion risks

• Standardized surgical workflows reduce brand-specific training needs
• DSOs standardize purchasing across brands based on price
• Increased use of guided surgery and digital planning reduces procedural variability

Leading indicators

• Training/course participation and certification counts
• Rep/clinical support coverage and engagement
• Clinic share-of-wallet and repeat ordering behavior

Counterarguments

• Clinicians can multi-source implants; retraining costs may be manageable
• Digital planning and standard kits can make switching easier over time

Erosion risks

• Shift to centralized procurement by DSOs and group practices
• Digital commerce reduces dependence on reps/distributors
• Distributor consolidation weakens bargaining position

Leading indicators

• Direct vs distributor mix
• DSO penetration and contract wins/losses
• Regional revenue growth vs market growth

Counterarguments

• Competitors also have global sales forces and distributor networks
• Channel partners can carry multiple brands, reducing exclusivity

Erosion risks

• Clinics multi-home on multiple aligner systems
• Open scanning and interoperable planning tools reduce switching costs
• Price competition and commoditization of aligner manufacturing

Leading indicators

• Case volumes per active provider
• Provider retention and repeat ordering
• Share of cases using remote monitoring tools

Counterarguments

• Dominant competitors offer similar digital tools and larger ecosystems
• Workflow tools may not meaningfully prevent switching if price/performance differs

Erosion risks

• Competitors also automate manufacturing and scale globally
• Regulatory or quality issues can disrupt production and increase costs
• Rapid price erosion as more entrants scale capacity

Leading indicators

• Gross margin trend in orthodontics-related sales
• Turnaround time / throughput metrics
• Automation-driven unit cost reductions

Counterarguments

• Market leader scale may remain materially larger, sustaining a cost advantage
• Manufacturing partnerships can be replicated and may not be exclusive

Erosion risks

• Open standards/interoperability reduce platform lock-in
• Clinics/labs prefer best-of-breed point solutions
• Regulatory/security incidents undermine trust in cloud workflows

Leading indicators

• Active users on the platform (clinicians/labs)
• Attach rate of scanners to platform workflows
• Software/service recurring revenue growth

Counterarguments

• Major incumbents and independents offer comparable end-to-end digital workflows
• If the platform is truly 'open', it may reduce exclusivity and monetization leverage

Erosion risks

• Hardware commoditization (scanners/printers) reduces differentiation
• Dental labs may resist vendor lock-in and demand open formats
• Competitors bundle at lower price points

Leading indicators

• Scanner installs and utilization
• Cross-sell rates (scanner -> software -> production/consumables)
• Renewal rates for software/services

Counterarguments

• Clinics can assemble similar workflows from multiple vendors
• Bundling can face pushback if any component is inferior to best-in-class alternatives